Immuron Ltd has released a press release.
NASDAQ Listing on Hold Pending NASH Interim Analysis Results
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immuron
- IMC Expands Agreement with US Army-3 Additional Therapeutics
- Completion of Manufacturing of Drug Product for C-Diff Trial
- IMC Form F1 - US Registration Statement (Prelim. Prospectus)
- Positive Results of IMM-124E in Acute Colitis Studies
- Close of Recruitment of Phase II NASH Trial
Later from Immuron
- Immuron Secures $1.5M R&D Cash Advance Loan Funding
- Travelan Increases Industry Presence - Conf & Sales Update
- IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M
- Pre-Clinical C. difficile Infection Results Paper Published
- NASH PhaseII Interim Analysis Reveals Improved Liver Enzymes
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron